On the 27th, Viatris Korea and Jeil Pharmaceutical announced that they will launch and co-promote the dyslipidemia treatment ‘Lipitor Plus (atorvastatin and ezetimibe)' from May 1st.

Jeil Pharmaceutical had received approval for Lipitor Plus from the Ministry of Food and Safety on February 18th, in 3 dosages - 10/10mg, 10/20mg, 10/40mg – for the treatment of primary hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH).

Lipitor Plus uses atorvastatin, the same active pharmaceutical ingredient (API) used in ‘Lipitor (atorvastatin).’ Jeil Pharmaceutical will manufacture the drug using the original API provided by Viatris Korea.

By adding L